Introduction
Enteric fever continues to remain a public health problem in many countries. In 2000, typhoid fever caused an estimated 21.7 million illnesses and 217 000 deaths, and paratyphoid fever caused an estimated 5.4 million illnesses worldwide.
1 In Asia, Crump et al reported a crude incidence of typhoid as 274 per 100 000 persons.
1 Salmonella enterica serotype Typhi and Salmonella enterica serotype Paratyphi A are the main causes of enteric fever in India; S. enterica serovar Typhi being predominant. 2 In 1999, Sinha et al found the incidence rate to be 9.8 per 1000 person years in an urban slum of North India. 3 However, in 2008, Ochlai et al who conducted their surveillance in an urban Antibiogram of S. typhi and S. paratyphi A in India Indian Network for Surveillance of Antimicrobial Resistance Group slum in Kolkata in eastern India, reported an incidence of 214.2 per 100 000/year. 4 After the first reported outbreak of chloramphenicol resistant S. enterica serovar Typhi in 1972, there has been a steady increase in the number of multidrug resistant (MDR) strains of S. enterica serovar Typhiresistance to ampicillin, chloramphenicol and trimethoprim-sulphamethoxazole -over the next two decades. With the increasing use of fluoroquinolones in the 1990s for treatment of enteric fever, there was a gradual decrease in MDR of S. enterica serovar Typhi with emergence of nalidixic acid resistant strains.
A network of microbiology laboratories ( I n d i a n N e t w o r k f o r S u r v e i l l a n c e o f Antimicrobial Resistance) at premier medical colleges and hospitals in India was formed with support from the World Health Organization (Figure 1 ). The network aims to monitor and 
Methods
This study was conducted over three years (January 2008 to December 2010) retrospectively. Each centre compiled their susceptibility data for S. enterica serovar Typhi and S. enterica serovar Paratyphi A isolates for the study period in a defined template. The data collection template included patient's location, source / specimen of isolation and the antibiotic susceptibility profiles. Blood cultures were done by the conventional microbiological techniques or automated systems in the participating centres. The identification of Salmonellae was done by the standard biochemical tests and confirmation was done by serotyping.
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The antibiotic susceptibility testing was performed at different study sites by the Kirby Bauer's' disc diffusion technique and / or by MIC testing, using CLSI recommendations. 6 One laboratory used the BSAC guidelines for antimicrobial testing and interpretations. 7 The antibiotics tested included ampicillin (10μg), co-trimoxazole (1.25/23.75 μg), ciprofloxacin (5 μg), nalidixic acid (30 μg), ceftriaxone (30 μg), and chloramphenicol(30 μg). Inoculum was prepared by making a direct saline suspension of isolated colonies selected from an 18-to 24-hour blood agar plate. Turbidity of the suspension was adjusted to achieve a turbidity equivalent to a 0.5 McFarland standard and five disks were applied on a 100mm Mueller Hinton agar plate as per CLSI guidelines / BSAC. E. coli ATCC 25922 was used as the quality control strain for disc diffusion.
Results
A total of 3275 isolates of Salmonellae causing enteric fever were included in the study. There were 2511 S. enterica serovar Typhi strains (430 in 2008, 694 in 2009 and 1387 in 2010) and 764 S. enterica serovar Paratyphi A strains (311, 217 and 236 in 2008 Paratyphi A strains (311, 217 and 236 in , 2009 Paratyphi A strains (311, 217 and 236 in and 2010 respectively) during the study period. These strains were isolated predominantly from blood culture. Few isolates from pus (3), stool (14) and urine (8) also were also included in the study.
The antibiotic susceptibility (by CLSI guidelines) for S. enterica serovar Typhi and S. enterica serovar Paratyphi A isolates for the study period are shown in Table 1  and Table 2 . Nalidixic acid resistance was high in both S. enterica serovar Typhi and S. enterica serovar Paratyphi A, being 82% and 93% respectively during the three-year period. Third generation cephalosporins were 100% susceptible in 2008. Resistance to third generation cephalosporins was seen in 3% of strains of S. enterica serovar Typhi in 2009 and in 1% S. enterica serovar Paratyphi A in 2010. Multidrug resistance (MDR) to ampicillin, chloramphenicol and cotrimoxazole in S. enterica serovar Typhi was observed in less than 5% isolates. The antibiogram for the isolates reported by BSAC guidelines is summarized in Table 3 . Amp-Ampicillin, Chl-Chloramphenicol, Sxt-Cotrimoxazole, Ctri -Ceftriaxone, Cip-Ciprofloxacin, NA-Nalidixic acid Amp-Ampicillin, Chl-Chloramphenicol, Sxt-Cotrimoxazole, Ctri -Ceftriaxone, Cip-Ciprofloxacin, NA-Nalidixic acid
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Discussion
Enteric fever continues to remain an important infection in endemic countries and to travelers to these areas. As observed in the present study, enteric fever in India is mainly caused by S. enterica serovar Typhi and S. enterica serovar Paratyphi A. Nalidixic acid resistance is high among both S. enterica serovar Typhi and S. enterica serovar Paratyphi A. Susceptibility to ampicillin, chloramphenicol and cotrimoxazole -traditional first line drugs for enteric fever treatment is good. Third generation cephalosporins continue to remain susceptible and are a useful choice for the treatment of enteric fever. The major strength of the study is that it had representations from 15 centres which used similar protocols for data collection. However, one limitation of this study is the fact that there was inadequate representation from eastern India.
In a study of six years (2000 to 2006) from north India, there were a predominance of S. enterica serovar Typhi (62%) , followed by 38% S. enterica serovar Paratyphi A. 
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A recent study from eastern India showed multidrug resistance in 11.9% and 15.6% of S. enterica serovar Typhi and S. enterica serovar Paratyphi A isolates respectively.
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The percentage of S. enterica serovar Typhi isolations were more than S. enterica serovar Paratyphi A. Similarly, we also had a larger number of S. enterica serovar Typhi isolates (77%) than S. enterica serovar Paratyphi A (23%).
Ray et al found that nalidixic acid (NA) susceptibility was a good marker for fluoroquinolone susceptibility but NA resistance had a poor predictive value for ciprofloxacin resistance.
12 They suggested that NA resistant isolates should be tested for ciprofloxacin MIC before deciding a change in therapeutic regimen. Nalidixic acid resistant isolates of S. enterica serovar Typhi and S. enterica serovar Paratyphi A had higher MIC's to fluoroquinolones as compared to the nalidixic acid susceptible ones. 13 In a study from Puducherry, south India, there was a high rate of ciprofloxacin resistance (8%) observed in S. enterica serovar Typhi, with 78% isolates being NA resistant.
14 They also reported a high rate of MDR S. enterica serovar Typhi (22%). Chitnis et al reported a gradually increasing MIC to ciprofloxacin from <=0.125 mg/L to > 1mg/L among the isolates of S. enterica serovar Typhi over the years 1988 to 2005. 15 Concurrently MDR, which was seen in upto 90% isolates in 1990-91 had declined to 5.6% in 2005. In view of the increasing MIC's of ciprofloxacin, there has been a suggestion to relook at the breakpoints and the zone diameters for reporting ciprofloxacin for Salmonella. 16 As per BSAC guidelines 2011 for ciprofloxacin for Salmonella, it is recommended that isolates In the present study, S . e n t e r i c a serovar Typhi susceptibility to ampicillin, chloramphenicol and cotrimoxazole was 93%, 96% and 95% respectively. This is similar to a study done in south India where there was a significant increase in sensitivity to chloramphenicol (86%), ampicillin (84%) and cotrimoxazole (88%). MDR was seen in 12% cases in the same study. 17 There is a marked reduction in the reduction of MDR isolates as compared to studies in early 2000. 10 The high prevalence of MDR among Salmonella species had led to fluoroquinolones assuming a primary role in the therapy. Some investigators have noted increases in the prevalence of S. enterica serovar Typhi and S. enterica serovar Paratyphi A strains susceptible to traditional first-line antimicrobials coinciding with a switch to fluoroquinolones for the management of enteric fever.
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Azithromycin has been seen to be efficacious for the treatment of typhoid fever; 19 however, there are reports of emergence of resistance to azithromycin. 20 There are sporadic reports of third generation cephalosporin resistance in Salmonella. Gokul et al. reported an ACC-1 AmpC β-lactamase producing S. enterica serovar Typhi. 21 However, third generation cephalosporins still continue to be a good option for the treatment of enteric fever.
To conclude, this study demonstrates the re-emergence of susceptibility to ampicillin, chloramphenicol and cotrimoxazole in Salmonella enterica serovar Typhi, a decline in MDR strains and a high resistance to nalidixic acid in India. Third generation cephalosporins seem to be effective therapeutic options.
